pyrazines has been researched along with Carcinoma, Papillary in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiappetta, G; Di Maro, G; Jarzab, B; Masullo, M; Monaco, M; Oczko-Wojciechowska, M; Orlandella, FM; Salerno, P; Salvatore, G; Santoro, M; Thomas, G; Unger, K | 1 |
| Adam, A; Barry, ER; Beran, G; Cairo, S; Clark, EA; D'Cruz, CM; Déas, O; Fawell, SE; Frigault, MM; Hattersley, M; Henry, RE; Jones, RD; Linsenmayer, D; Nicolle, D; Reimer, C; Schuller, AG; Smith, A; Wilson, J; Zinda, M | 1 |
| Arndt, T; Bartsch, DK; Brendel, C; Fischer, M; Greene, BH; Hinterseher, U; Hoffmann, S; Ramaswamy, A; Roth, S; Wunderlich, A | 1 |
| Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A | 1 |
| Dai, G; Wang, X | 1 |
1 review(s) available for pyrazines and Carcinoma, Papillary
| Article | Year |
|---|---|
[Development of bladder cancer chemoprevention].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Papillary; Humans; Neoplasm Recurrence, Local; Piroxicam; Pyrazines; Retinoids; Thiones; Thiophenes; Urinary Bladder Neoplasms | 2003 |
1 trial(s) available for pyrazines and Carcinoma, Papillary
| Article | Year |
|---|---|
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2012 |
3 other study(ies) available for pyrazines and Carcinoma, Papillary
| Article | Year |
|---|---|
Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Endoplasmic Reticulum Stress; Gene Knockdown Techniques; Humans; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Oxidation-Reduction; Protein Disulfide-Isomerases; Proteins; Pyrazines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Up-Regulation | 2014 |
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Papillary; Carcinoma, Renal Cell; Cell Line, Tumor; Crizotinib; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Indoles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyrroles; Sunitinib; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
Topics: Adenocarcinoma, Follicular; Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma; Carcinoma, Papillary; Caspase 3; Cell Cycle Checkpoints; Cell Proliferation; Flow Cytometry; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; NF-kappa B; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thyroid Neoplasms; Tumor Cells, Cultured | 2012 |